We and others have previously shown that loss of PTEN expression, which occurs in 30% of sporadic cases, is associated with lack of response to cetuximab [24], and that PIK3CA/PTEN deregulation may be a biomarker of resistance in KRAS wild-type patients [25], [26] and cellular models of CRC [27]. Here, PTEN is linked to colorectal carcinoma.